XOMA Royalty Files Definitive Proxy for Ligand Merger, Details $39 Cash Plus Contingent Value Right
XOMA sits 87% above its 52-week low of $22.29 on light trading volume (0.1× avg).
Summary
XOMA Royalty Corp filed its definitive proxy statement detailing the terms of its acquisition by Ligand Pharmaceuticals for $39.00 per share in cash plus one contingent value right (CVR) per share, with a shareholder vote scheduled to approve the merger.
Key Events · M&A and Partnerships · XOMA
-
Merger Agreement Details
XOMA Royalty Corp will be acquired by Ligand Pharmaceuticals for $39.00 per share in cash, plus one contingent value right (CVR) per share. The merger agreement was originally dated April 27, 2026, and amended on May 16, 2026.
-
Contingent Value Rights (CVRs)
Each CVR represents a contractual right to receive contingent cash payments derived from the net proceeds of the Janssen Litigation. These CVRs are highly contingent, non-transferable, will not be listed or traded, and may ultimately have no value. For tax purposes, the company estimates an implied value of approximately $1.84 per CVR.
-
Shareholder Vote Required
The merger requires approval from XOMA Royalty stockholders at a special meeting. The board of directors unanimously recommends voting 'FOR' the merger agreement and a related holding company reorganization.
-
Significant Shareholder Support
Officers, directors, and certain funds affiliated with BVF Partners, collectively holding over 40% of the voting shares, have signed voting agreements to support the merger, increasing the likelihood of approval.
Analysis · XOMA · Life Sciences
This filing is the definitive proxy statement/prospectus for the previously announced acquisition of XOMA Royalty by Ligand Pharmaceuticals. It provides shareholders with all the necessary details to vote on the merger, which includes a fixed cash component of $39.00 per share and a contingent value right (CVR) tied to the outcome of the Janssen Litigation. The board's unanimous recommendation and the voting agreements from major shareholders (representing over 40% of voting shares) significantly increase the likelihood of the merger's approval. The CVRs, while offering potential upside, are highly speculative and non-transferable, adding a layer of uncertainty to the total value shareholders will receive. The market is currently pricing the stock above the cash offer, suggesting an expectation of value from the CVRs or a potential for a higher bid.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 44% of the 972 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XOMA was trading at $41.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $522M. The 52-week trading range was $22.29 to $42.81. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.